ASCL2 Maintains Stemness Phenotype through ATG9B and Sensitizes Gliomas to Autophagy Inhibitor
Lihong Wang, Ye Yuan, Jiao Wang, Ying Luo, Yang Lan, Jia Ge, Lei Li, Feng Liu, Qing Deng, Zexuan Yan, Mei Liang, Sen Wei, Xindong Liu, Yan Wang, Yi‐Fang Ping, Yu Shi, Shi‐Cang Yu, Xia Zhang, You‐Hong Cui, Xiaohong Yao, Hua Feng, Tao Luo, Xiu‐Wu Bian
Abstract
Abstract Autophagy is a highly conserved process that is vital for tumor progression and treatment response. Although autophagy is proposed to maintain the stemness phenotype in adult diffuse glioma, the molecular basis of the link between autophagy and stemness is poorly understood, which makes it impossible to effectively screen for the population that will benefit from autophagy‐targeted treatment. Here, ATG9B as essential for self‐renewal capacity and tumor‐propagation potential is identified. Notably, ASCL2 transcriptionally regulates the expression of ATG9B to maintain stemness properties. The ASCL2‐ATG9B axis is an independent prognostic biomarker and indicator of autophagic activity. Furthermore, the highly effective blood–brain barrier (BBB)‐permeable autophagy inhibitor ROC‐325, which can significantly inhibit the progression of ASCL2‐ATG9B axis High gliomas as a single agent is investigated. These data demonstrate that a new ASCL2‐ATG9B signaling axis is crucial for maintaining the stemness phenotype and tumor progression, revealing a potential autophagy inhibition strategy for adult diffuse gliomas.